Antimicrobial resistance among enteric pathogens

Seminars in Pediatric Infectious Diseases

Volumn 15, Issue 2, 2004, Pages 71-77

  Pickering, Larry K ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SHIGA TOXIN; STREPTOMYCIN; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE;

AEROMONAS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CAMPYLOBACTER COLI; CAMPYLOBACTER JEJUNI; CHILD; CLOSTRIDIUM DIFFICILE; CROSS RESISTANCE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ESCHERICHIA COLI; GASTROENTERITIS; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; INTESTINE FLORA; PROTOZOAL INFECTION; REVIEW; SALMONELLA; SALMONELLA ENTERITIDIS; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SHIGELLA; SIDE EFFECT; VIBRIO; YERSINIA ENTEROCOLITICA;

ANTI-BACTERIAL AGENTS; CAMPYLOBACTER; CHILD; CHILD, PRESCHOOL; DIARRHEA; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; SALMONELLA; SHIGELLA;

EID: 3042756604     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.spid.2004.01.009     Document Type: Review

References (69)

1. King C.K., Glass R., Bresee J.S., et al. Centers for Disease Control and Prevention. Managing acute gastroenteritis among children oral rehydration, maintenance, and nutritional therapy. MMWR. 52:(RR-16):2003;1-16
2. Pickering L.K., Cleary T.G. Therapy for diarrheal illness in children. Blaser M.J., Smith P.D., Ravdin J.I. Infections of the Gastrointestinal Tract. 2nd ed. 2002;1223-1240 Raven Press, New York
3. Tenover F.C. Development and spread of bacterial resistance to antimicrobial agents an overview. Clin Infect Dis Suppl. 33:2001;S108-S115
4. Angulo F.J., Johnson K.R., Tauxe R.V., et al. Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella Implications for the use of fluoroquinolones in food animals. Microb Drug Resist. 6:2000;77-83
5. Angulo F.J., Baker N.L., Olsen S. Antimicrobial use in agriculture - controlling the transfer of antimicrobial resistance in humans. Semin Pediatr Infect Dis. 15:2004;78-85
6. National Center for Infectious Diseases. Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria Website. Available at: www.cdc.gov/NARMS
7. Chiu C.H., Lin T.Y., Ou J.T. A clinical trial comparing oral azithromycin, cefixime and no antibiotics in the treatment of acute uncomplicated Salmonella enteritis in children. J Paediatr Child Health. 35:1999;372-374
8. Sirinavin S., Garner P. Antibiotics for treating Salmonella gut infections. Cochrane Database Syst Rev. 2000;. CD001167
9. Wong C.S., Jelacis S., Habeeb R.L., et al. The risk of the hemolytic uremic syndrome after antibody treatment of Escherichia coli 0157 H7 infections. N Engl J Med. 342:2000;1930-1936
10. Pickering L.K. Antimicrobial therapy of E. coli 0157 H7 infections. Pediatr Infect Dis J. 20:2001;465-466
11. Safdar N., Said A., Gangnon Re., et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli 1057:H7 enteritis. A meta-analysis. JAMA. 288:2002;996-1000
12. Ohara T., Kojio S., Taneike I., et al. Effects of azithromycin on Shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Ag Chemother. 46:2002;3478-3483
13. Eng J.V., Marcus R., Hadler J.L., et al. Consumer attitudes and use of antibiotics. Emerg Infect Dis. 9:2003;1128-1135
14. Magee J.T., Pritchard E.L., Fitzgerald K.A., et al. Antibiotic prescribing and antibiotic resistance in community practice retrospective study, 1996-8. BMJ. 319:1999;1239-1240
15. Institute of Medicine. The Resistance Phenomenon in Microbes and Infectious Disease Vectors Implications for Human Health and Strategies for Containment-Workshop Summary. 2003
16. World Health Organization Containing Antimicrobial Resistance Review of the literature and report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance. 1999;. Geneva, Switzerland, February 4-5
17. Kuschner R.A., Trofa A.F., Thomas R.J., et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis. 21:1995;536-541
18. Talsma E., Goettsch W.G., Nieste H.L., et al. Resistance in Campylobacter species increased resistance to fluoroquinolones and seasonal variation. Clin Infect Dis. 29:1999;845-848
19. Engberg J., Aarestrup F.M., Taylor D.E., et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli resistance mechanisms and trends in human isolates. Emerg Infect Dis. 7:2001;24-34
20. th International Workshop on Campylobacter, Helicobacter and Related Organisms. 2001;. Freiburg, Germany, Sept 1-5 Int J Med Microbiol. 291:(suppl 31):2001;9
21. th International Workshop on Campylobacter, Helicobacter and Related Organisms. 2001;. Freiburg, Germany, Sept 1-5 Int J Med Microbiol. 2919:(suppl 31):2001
22. Gaudreau C., Gilbert H. Antimicrobial resistance of clinical strains of Campylobacter jejuni subsp jejuni isolated from 1985 to 1997 in Quebec, Canada. Antimicrob Agents Chemother. 42:1998;2106-2108
23. Yan W., Taylor D.E. Characterization of erythromycin resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 35:1991;1989-1996
24. Coker A.O., Adefeso A.O. The changing patterns of Campylobacter jejuni/coli in Lagos, Nigeria after ten years. East Afr Med J. 71:1994;437-440
25. Hoge C.W., Gambel J.M., Srijan A., et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 26:1998;341-345
26. Sanders J.W., Isenbarger D.W., Walz S.E., et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 67:2002;533-538
27. Reina J., Ros M.J., Serra A. Susceptibilities to 10 antimicrobial agents of 1, 220 Campylobacter strains isolated from 1987 to 1993 from feces of pediatric patients. Antimicrob Agents Chemother. 38:1994;2917-2920
28. Sanchez R., Fernandez-Baca V., Diaz M.D., et al. Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrob Agents Chemother. 38:1994;1879-1882
29. Saenz Y., Zarazaga M., Lantero M., et al. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrob Agents Chemother. 44:2000;267-271
30. Li C.C., Chiu C.N., Wu J.L., et al. Antimicrobial susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J Infect Dis. 30:1998;39-42
31. Gaudreau C., Michaud S. Cluster of erythromycin- and ciprofloxacin- resistant Campylobacter jejuni subsp. jejuni from 1999 to 2001 in men who have sex with men, Quebec, Canada. Clin Infect Dis. 37:2003;131-136
32. Taylor D.E., Chang N. In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. Antimicrob Agents Chemother. 35:1991;1917-1918
33. Chatzipanagiotou S., Papavasileiou E., Lakumenta A., et al. Antimicrobial susceptibility patterns of Campylobacter jejuni strains isolated from hospitalized children in Athens, Greece. J Antimicrob Chemother. 49:2002;803-805
34. Wagner J., Jabbusch M., Eisenblatter M., et al. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline. Antimicrob Agents Chemother. 47:2003;2358-2361
35. Sjogren E., Lindblom G.B., Kaijser B. Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patients. J Antimicrob Chemother. 40:1997;257-261
36. Prasad K.N., Mathur S.K., Dhole T.N., et al. Antimicrobial susceptibility and plasmid analysis of Campylobacter jejuni isolated from diarrhoeal patients and healthy chickens in northern India. J Diarrhoeal Dis Res. 12:1994;270-273
37. Isenbarger D.W., Hoge C.W., Srijan A., et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis. 8:2002;175-180
38. Sam W.I., Lyons M.M., Waghorn D.J. Increasing rates of ciprofloxacin resistant Campylobacter. J Clin Pathol. 52:1999;709
39. Rautelin H., Vierikko A., Hänninen J.L., et al. Antimicrobial susceptibilities of Campylobacter strains isolated from Finnish subjects infected domestically or from those infected abroad. Antimicrob Agents Chemother. 47:2003;102-105
40. Navarro F., Miro E., Fuentes I., et al. Campylobacter species identification and resistance to quinolones. Clin Infect Dis. 17:1993;815-816
41. Segreti J., Gootz T.D., Goodman L.J., et al. High-level quinolone resistance in clinical isolates of Campylobacter jejuni. J Infect Dis. 165:1992;667-670
42. Smith K.E., Besser J.M., Hedberg C.W., et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med. 340:1999;1525-1532
43. th International Workshop on Campylobacter, Helicobacter and Related Organisms. 2001;. Freiburg, Germany, Sept 1-5 Int J Med Microbiol. 291:(suppl 31):2001;9
44. th International Workshop on Campylobacter, Helicobacter and Related Organisms. 2001;. Freiburg, Germany, Sept 1-5 Int J Med Microbiol. 291:(suppl 31):2001;6
45. th International Workshop on Campylobacter, Helicobacter and Related Organisms. 2001;. Freiburg, Germany, Sept 1-5 Int J Med Microbiol. 291:(suppl 31):2001;9
46. Hakanen A., Jousimies-Somer H., Siitonen A., et al. Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland association of ciprofloxacin resistance to travel destination. Emerg Infect Dis. 9:2003;267-270
47. Gaudreau C., Gilbert H. Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montreal, Canada. Antimicrob Agents Chemother. 47:2003;2027-2029
48. Krausse R., Ullmann U. In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob Agents Chemother. 47:2003;2946-2950
49. Murray B.E. Problems and mechanisms of antimicrobial resistance. Infect Dis Clin North Am. 3:1989;423-439
50. Replogle M.L., Fleming D.W., Cieslak P.R. Emergence of antimicrobial-resistant shigellosis in Oregon. Clin Infect Dis. 30:2000;515-519
51. Griffin P.M., Tauxe R.V., Redd S.C., et al. Emergence of highly trimethoprim-sulfamethoxazole-resistant Shigella in a native American population an epidemiologic study. Am J Epidemiol. 129:1989;1042-1051
52. Cheasty T., Skinner J.A., Rowe B., et al. Increasing incidence of antibiotic resistance in Shigellas from humans in England and Wales recommendations for therapy. Microb Drug Resist. 4:1998;57-60
53. Harnett N. High level resistance to trimethoprim, cotrimoxazole and other antimicrobial agents among clinical isolates of Shigella species in Ontario, Canada - an update. Epidemiol Infect. 109:1992;463-472
54. Aleksic S., Katz A., Aleksic V., et al. Antibiotic resistance of Shigella strains isolated in the Federal Republic of Germany 1989-1990. Zentralbl Bakteriol. 279:1993;484-493
55. Sanchez C., Garcia-Restoy E., Garau J., et al. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis a double-blind trial. J Infect Dis. 168:1993;1304-1307
56. Rosenthal S.L. Exacerbation of Salmonella enteritis due to ampicillin. N Engl J Med. 280:1969;147-148
57. Aserkoff B., Bennett J.V. Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of Salmonellae. N Engl J Med. 281:1969;636-640
58. Neill M.A., Opal S.M., Heelan J., et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis experience during an outbreak in health care workers. Ann Intern Med. 114:1991;195-199
59. Mourad A.S., Metwally M., el Deen A.N., et al. Multiple-drug-resistant Salmonella typhi. Clin Infect Dis. 17:1993;135-136
60. Molbak K., Baggesen D.L., Aarestrup F.M., et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT104. N Engl J Med. 341:1999;1420-1425
61. Molbak K., Gerner-Smidt P., Wegener H.C. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg Infect Dis. 8:2002;514-515
62. Threlfall E.J., Ward L.R. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerg Infect Dis. 7:2001;448-450
63. Vahaboglu H., Fuzi M., Cetin S., et al. Characterization of extended-spectrum beta-lactamase (TEM-52)-producing strains of Salmonella enterica serovar Typhimurium with diverse resistance phenotypes. J Clin Microbiol. 39:2001;791-793
64. van Duijkeren E., Wannet W.J., Houwers D.J., et al. Antimicrobial susceptibilities of Salmonella strains isolated from humans, cattle, pigs, and chickens in the Netherlands from 1984 to 2001. J Clin Microbiol. 41:2003;3574-3578
65. Villa L., Mammina C., Miriagou V., et al. Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype Enteritidis clinical isolates in southern Italy. J Clin Microbiol. 40:2002;2662-2665
66. Schroeder C.M., Meng J., Zhao S., et al. Antimicrobial resistance of Escherichia coli O26, O103, O111, O128, and O145 from animals and humans. Emerg Infect Dis. 8:2002;1409-1414
67. Helms M., Vastrup P., Gerner-Smidt P., et al. Excess mortality associated with antimicrobial drug-resistant Salmonella Typhimurium. Emerg Infect Dis. 8:2002;490-495
68. Nakaya H., Yasuhara A., Yoshimura K., et al. Life-threatening infantile diarrhea from fluoroquinolone-resistant Salmonella enterica Typhimurium with mutations in both gyrA and parC. Emerg Infect Dis. 9:2003;255-257
69. Bhutta Z.A., Khan I.A., Shadmani M. Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children a randomized controlled trial in Pakistan. Antimicrob Agents Chemother. 44:2000;450-452